Nifuroxazide

Nifuroxazide is a nitrofuran antibiotic.¹ It is active against strains of the enteropathogenic bacteria C. jejuni, Salmonella, Y. enterocolitica, Shigella, and E. coli.¹ It inhibits quorum sensing and virulence factor production in P. aeruginosa.² Nifuroxazide inhibits STAT3 activity in a reporter assay (IC₅₀ = ~3 µM) and decreases viability of U266 and INA-6 myeloma cells, which have constitutive STAT3 phosphorylation, with EC₅₀ values of approximately 4.5 µM for both.³ It also decreases viability, migration, and invasion of, and induces apoptosis in, MCF-7, 4T1, and MDA-MB-231 breast cancer cells.⁴ Nifuroxazide (50 mg/kg per day) reduces tumor growth and prevents pulmonary metastasis in a 4T1 murine mammary carcinoma model. It also reduces diarrhea, weight loss, and colon inflammation in a rat model of acetic acid-induced ulcerative colitis.⁵

WARNING This product is not for human or veterinary use.

1. Vanhoof, R., Coignau, H., Stas, G., et al. Evaluation of the in vitro activity of nifuroxazide on enteropathogenic microorganisms: Determination of bacteriostatic and bactericidal concentrations and disk susceptibility. Acta Clin. Belg. 36(3), 126-129 (1981).

2. Yang, L., Rybtke, M.T., Jakobsen, T.H., et al. Computer-aided identification of recognized drugs as Pseudomonas aeruginosa quorum-sensing inhibitors. Antimicrob. Agents Chemother. 53(6), 2432-2443 (2009).

3. Nelson, E.A., Walker, S.R., Kepich, A., et al. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood 112(13), 5095-5102 (2008).

4. Yang, F., Hu, M., Lei, Q., et al. Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model. Cell Death Dis. 6(3), e1701 (2015).

5. El-Far, Y.M., Elsherbiny, N.M., El-Shafey, M., et al. The interplay of the inhibitory effect of nifuroxazide on NF-κB/STAT3 signaling attenuates acetic acid-induced ulcerative colitis in rats. Environ. Toxicol. Pharmacol. 79, 103433 (2020).